Literature DB >> 16432453

Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression.

Lukasz Kuźbicki1, Agnieszka Sarnecka, Barbara W Chwirot.   

Abstract

Cyclooxygenase-2 (COX-2) is an enzyme that plays an important role in the production of prostaglandins. Numerous studies have demonstrated increased levels of COX-2 in human cancers of different types. It is thought that COX-2 may be involved in the development and progression of malignant tumours. However, data on the changes in COX-2 expression during the development and progression of human melanoma are relatively limited. Moreover, the results reported by different groups disagree to a large extent. The aim of this work was to evaluate whether COX-2 protein might be considered a potential molecular marker of melanoma progression. The expression of COX-2 was determined immunohistochemically in formalin-fixed, paraffin-embedded specimens of 64 human melanocytic skin tumours (17 naevi, 36 primary cutaneous melanomas and 11 lymph node melanoma metastases, with six pairs of primary and metastatic lesions obtained from the same patients). It was found that the expression level of COX-2 was dependent on both the stage and histopathological type of the melanoma. Collectively, our data indicate that changes in the expression level of COX-2 are correlated with the development and progression of human melanoma, and imply that the COX-2 protein may be considered a potential prognostic and predictive marker in malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16432453     DOI: 10.1097/01.cmr.0000194430.77643.a0

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  16 in total

Review 1.  Melanoma inhibition by cyclooxygenase inhibitors: role of interleukin-6 suppression, a putative mechanism of action, and clinical implications.

Authors:  R E Kast
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

2.  Expression and significance of factors related to angiogenesis in choroidal melanoma.

Authors:  Qiang Xu; Gui-Qiu Zhao; Jie Zhao; Hong Lin; Ying-Ying Mou; Qing Wang; Wei-Rong Sun
Journal:  Int J Ophthalmol       Date:  2011-02-18       Impact factor: 1.779

3.  Antitumor effects of celecoxib in COX-2 expressing and non-expressing canine melanoma cell lines.

Authors:  Kyoung-Won Seo; Ye-Rin Coh; Robert B Rebhun; Jin-Ok Ahn; Sei-Myung Han; Hee-Woo Lee; Hwa-Young Youn
Journal:  Res Vet Sci       Date:  2014-03-20       Impact factor: 2.534

Review 4.  Melanoma Chemoprevention: Current Status and Future Prospects.

Authors:  Gagan Chhabra; Mary Ann Ndiaye; Liz Mariely Garcia-Peterson; Nihal Ahmad
Journal:  Photochem Photobiol       Date:  2017-04-27       Impact factor: 3.421

5.  Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanoma.

Authors:  Bonnie E Gould Rothberg; David L Rimm
Journal:  J Invest Dermatol       Date:  2010-06-17       Impact factor: 8.551

6.  Prostaglandin-E2 is produced by adult human epidermal melanocytes in response to UVB in a melanogenesis-independent manner.

Authors:  Karl Gledhill; Lesley E Rhodes; Margaret Brownrigg; Ann K Haylett; Mojgan Masoodi; Anthony J Thody; Anna Nicolaou; Desmond J Tobin
Journal:  Pigment Cell Melanoma Res       Date:  2010-03-17       Impact factor: 4.693

7.  Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women: the Women's Health Initiative.

Authors:  Christina A Gamba; Susan M Swetter; Marcia L Stefanick; Jessica Kubo; Manisha Desai; Katrina M Spaunhurst; Animesh A Sinha; Maryam M Asgari; Susan Sturgeon; Jean Y Tang
Journal:  Cancer       Date:  2013-03-11       Impact factor: 6.860

Review 8.  Current and future trials of targeted therapies in cutaneous melanoma.

Authors:  Matthew S Evans; Subbarao V Madhunapantula; Gavin P Robertson; Joseph J Drabick
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

Review 9.  Aspirin and other NSAIDs as chemoprevention agents in melanoma.

Authors:  James R Goodman; Douglas Grossman
Journal:  Cancer Prev Res (Phila)       Date:  2014-04-02

10.  NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma.

Authors:  R J Flockhart; J L Armstrong; N J Reynolds; P E Lovat
Journal:  Br J Cancer       Date:  2009-09-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.